Targeted intracellular delivery of antitubercular agents by functionalized nanocapsules

Project description

Nanotechnology-based intracellular drug delivery to target Mycobacterium tuberculosis

Tuberculosis (TB) is a major global public health problem with an alarming increase of multidrug-resistant cases. TB is caused by Mycobacterium tuberculosis that can survive inside host cells, mainly in macrophages. The intracellular elimination of these bacteria is more efficient with delivery of host cell-directed therapeutics. The EU-funded TBNANO project aims to develop and evaluate antitubercular drug-loaded nanocapsules capable of targeting host cell molecules. The surface of the nanocapsules will be functionalised with macrophage-targeting peptides and mannose derivatives. This nanotechnology-based drug delivery will enhance cellular uptake by the host macrophages, resulting in the efficient targeting of the intracellular mycobacteria, while reducing the undesirable drug side effects.

Fields of science

• medical and health sciences › health sciences › public health
• natural sciences › biological sciences › microbiology › bacteriology
• medical and health sciences › health sciences › infectious diseases
• medical and health sciences › clinical medicine › pneumology › tuberculosis
• natural sciences › biological sciences › biochemistry › biomolecules › carbohydrates

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Net EU contribution

€ 172 932,48

Address

Calle Serrano 117
28006 Madrid
Spain

Region

Comunidad de Madrid › Comunidad de Madrid › Madrid

Activity type

Research Organisations

Links

Other funding

€ 0,00